The Personalized Cancer Care Program at Floating Hospital for Children has set it sails towards the Cancer Moonshot 2020, in order to reach our ultimate destination in making childhood cancer a more managable and controlable disease. As one of the 10 founding members of the Pediatric Consortium, we are committed to apply the most comprehensive cancer molecular diagnostic testing available—integrating whole genomic and proteomic analysis and leverage proven and promising combination immunotherapies and clinical trials. The Cancer Moonshot 2010 will implement real time data sharing infrastructure in order to accelerate clinical learning and insight to all consortium members.
“This is the most exciting time in oncology. For the first time in many decades, we have the tools and understanding to abandon the old paradigm of killing cancer and develop more individualized, rational, and much less toxic approaches,” desribes Giannoula Lakka Klement, MD, director of the Personalized Cancer Program.
The Floating Hospital has been using proetomic and genomic diagnosistic testing to create and treat patients with individualized combinatory molecular therapies for since 2010. By coupling combination molecular therapies with low dose metronomic chemotherapy, we are able to minimize side-effects while maintaining treatment response. We are excited to expand our local vision to a national level with the Cancer Moonshot 2020 collaboration.
Dr. Klement specializes in molecular therapeutics and the treatment of brain tumors, rare tumors and vascular anomalies. Her laboratory research encompasses tumor and wound angiogenesis, with emphasis on the role of platelets in angiogenesis. As one of the founders of metronomic chemotherapy, Dr. Klement has positioned Floating Hospital for Children as leader changing the paradigm of cancer into a treatable disease.
Cancer MoonShot 2020 is the nation's most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit http://www.CancerMoonShot2020.org or watch the video below.